Wang Jie, Yuan Hui, Xu Jianan, Yang Chongyi
Department of Urology, Ninghai First Hospital, Zhejiang, People's Republic of China.
Cancer Manag Res. 2025 Sep 1;17:1859-1869. doi: 10.2147/CMAR.S538367. eCollection 2025.
Prostate cancer (PCa) is the most common tumor for men in the genital system. Despite several new therapies approved in the past decades, 34,700 patients die on a regular basis in 2023 in America. Recently radioisotopic therapies have shown the delightful results in the PCa treatment, which made FDA approved lutetium-177 for adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castrate-resistant prostate cancer (mCRPC). Many other clinical trials are also in progress in various settings. Both monotherapy and combination studies are underway. However, because of several limitations existed in these clinical trials and alarmed long-term nephrotoxicity of PSMA-targeted therapy, we should be more prudent to this therapy. In this review, we evaluates the evolving clinical and preclinical landscape of PSMA-targeted therapy, as well as the potential biomarkers for evaluating the therapeutic response.
前列腺癌（PCa）是男性生殖系统中最常见的肿瘤。尽管在过去几十年中批准了几种新疗法，但2023年美国仍有34700名患者定期死亡。最近，放射性同位素疗法在前列腺癌治疗中显示出令人满意的结果，这使得美国食品药品监督管理局（FDA）批准了镥-177用于治疗前列腺特异性膜抗原（PSMA）阳性的转移性去势抵抗性前列腺癌（mCRPC）成年患者。许多其他临床试验也在不同环境中进行。单药治疗和联合研究都在进行中。然而，由于这些临床试验存在一些局限性，且PSMA靶向治疗存在令人担忧的长期肾毒性，我们对这种治疗应更加谨慎。在本综述中，我们评估了PSMA靶向治疗不断发展的临床和临床前情况，以及用于评估治疗反应的潜在生物标志物。
